Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
Plasma homovanillic acid (HVA), but not plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), was substantially increased in 4 patients undergoing hemodialysis, 3 patients with chronic renal failure, and 3 patients receiving carbidopa/levodopa for Parkinson's disease. These conditions should be considered in psychiatric research involving plasma HVA.